MT Newswires
Market Chatter: CME CEO Warns Against US Government Intervention in Oil Futures Markets Amid Iran War
⚠️
AI Sentiment
Highly Negative
1/10
- Home
- CME
CME
CME Group Inc.
as of 03-13-2026 3:56pm EST
$311.43
+$0.24
+0.08%
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
| Founded: | 1898 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 106.9B | IPO Year: | 2002 |
| Target Price: | $295.62 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 11.16 | EPS Growth: | 15.41 |
| 52 Week Low/High: | $248.63 - $329.16 | Next Earning Date: | 05-06-2026 |
| Revenue: | $6,520,600,000 | Revenue Growth: | 6.37% |
| Revenue Growth (this year): | 7.75% | Revenue Growth (next year): | 5.28% |
| P/E Ratio: | 27.88 | Index: | |
| Free Cash Flow: | 4.2B | FCF Growth: | +16.60% |
AI-Powered CME Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 73.49%
73.49%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CME Group Inc. (CME)
Vroman Ken
Sell
Chief Transformation Officer
CME Mar 12, 2026
Avg Cost/Share
$309.00
Shares
5,160
Total Value
$1,594,440.00
Owned After
14,910
SEC Form 4
Cook Elizabeth A
Sell
Director
CME Mar 6, 2026
Avg Cost/Share
$320.00
Shares
1,000
Total Value
$320,000.00
Owned After
17,771
SEC Form 4
Durkin Bryan T
Sell
Director
CME Feb 23, 2026
Avg Cost/Share
$309.65
Shares
4,200
Total Value
$1,300,530.00
Owned After
43,007
SEC Form 4
GEPSMAN MARTIN J
Sell
Director
CME Feb 20, 2026
Avg Cost/Share
$305.90
Shares
300
Total Value
$91,770.00
Owned After
24,999
SEC Form 4
Suskind Dennis
Sell
Director
CME Feb 6, 2026
Avg Cost/Share
$300.00
Shares
748
Total Value
$224,400.00
Owned After
2,699
SEC Form 4
SHEPARD WILLIAM R
Buy
Director
CME Dec 30, 2025
Avg Cost/Share
$278.37
Shares
262
Total Value
$73,008.10
Owned After
258,709.76
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Vroman Ken | CME | Chief Transformation Officer | Mar 12, 2026 | Sell | $309.00 | 5,160 | $1,594,440.00 | 14,910 | |
| Cook Elizabeth A | CME | Director | Mar 6, 2026 | Sell | $320.00 | 1,000 | $320,000.00 | 17,771 | |
| Durkin Bryan T | CME | Director | Feb 23, 2026 | Sell | $309.65 | 4,200 | $1,300,530.00 | 43,007 | |
| GEPSMAN MARTIN J | CME | Director | Feb 20, 2026 | Sell | $305.90 | 300 | $91,770.00 | 24,999 | |
| Suskind Dennis | CME | Director | Feb 6, 2026 | Sell | $300.00 | 748 | $224,400.00 | 2,699 | |
| SHEPARD WILLIAM R | CME | Director | Dec 30, 2025 | Buy | $278.37 | 262 | $73,008.10 | 258,709.76 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 4, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 4, 2026 · 100% conf.
AI Prediction SELL
1D
+0.33%
$295.61
5D
-1.69%
$289.65
20D
+1.68%
$299.58
Price: $294.62 Prob +5D: 0% AUC: 1.000
0001156375-26-000006
cme-20260204false000115637500011563752026-02-042026-02-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) February 4, 2026
CME GROUP INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 001-31553 36-4459170 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)
20 South Wacker DriveChicagoIllinois 60606 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (312) 930-1000 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered Class A Common StockCMENasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
The information set forth under “Item 2.02. Results Of Operations and Financial Condition,” including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. Attached and incorporated herein by reference as Exhibit 99.1 is a copy of a press release of CME Group Inc. dated February 4, 2026, reporting CME Group Inc.’s financial results for the quarter and year ended December 31, 2025. To supplement CME Group’s financial statements on a GAAP basis, the attached press release includes financial measures that are not in accordance with GAAP, consisting of non-GAAP revenues, expenses, operating income, net income and earnings per share. Management believes that the presentation of non-GAAP revenues, expenses, operating income, net income and earnings per share provide important supplemental information to management and investors about financial and business trends relating to CME Group Inc.’s financial condition and results of operations. Management believes that the use of these non-GAAP financial measures provide a better measure of comparability with the Company’s prior financial reports. Management acknowledges that non-GAAP adjustments may include recurring items. These non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Pursuant to the requirements of Regulation G, CME Group Inc. has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in the press release.
Item 9.01Financial Statements and Exhibits.
Exhibit Number Description
99.1 Press Release, dated February 4, 2026.
104 The cover page from CME Group Inc.'s Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CME Group Inc. Registrant
Date: February 4, 2026 By: /s/ Lynne Fitzpatrick Name:
Title: Lynne Fitzpatrick
Senior Managing Director, President and Chief Financial Officer
Principal Financial Offer and Duly Authorized Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 22, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 22, 2025
0001156375-25-000204
cme-20251022false000115637500011563752025-10-222025-10-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) October 22, 2025
CME GROUP INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 001-31553 36-4459170 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)
20 South Wacker DriveChicagoIllinois 60606 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (312) 930-1000 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered Class A Common StockCMENasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
The information set forth under “Item 2.02. Results Of Operations and Financial Condition,” including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. Attached and incorporated herein by reference as Exhibit 99.1 is a copy of a press release of CME Group Inc. dated October 22, 2025, reporting CME Group Inc.’s financial results for the quarter ended September 30, 2025. To supplement CME Group’s financial statements on a GAAP basis, the attached press release includes financial measures that are not in accordance with GAAP, consisting of non-GAAP revenues, expenses, operating income, net income and earnings per share. Management believes that the presentation of non-GAAP revenues, expenses, operating income, net income and earnings per share provide important supplemental information to management and investors about financial and business trends relating to CME Group Inc.’s financial condition and results of operations. Management believes that the use of these non-GAAP financial measures provide a better measure of comparability with the Company’s prior financial reports. Management acknowledges that non-GAAP adjustments may include recurring items. These non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Pursuant to the requirements of Regulation G, CME Group Inc. has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in the press release.
Item 9.01Financial Statements and Exhibits.
Exhibit Number Description
99.1 Press Release, dated October 22, 2025.
104 The cover page from CME Group Inc.'s Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CME Group Inc. Registrant
Date: October 22, 2025 By: /s/ Lynne Fitzpatrick Name:
Title: Lynne Fitzpatrick
Senior Managing Director, President and Chief Financial Officer
Principal Financial Offer and Duly Authorized Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 23, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 23, 2025
0001156375-25-000176
cme-20250723false000115637500011563752025-07-232025-07-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) July 23, 2025
CME GROUP INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 001-31553 36-4459170 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)
20 South Wacker DriveChicagoIllinois 60606 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (312) 930-1000 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered Class A Common StockCMENasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
The information set forth under “Item 2.02. Results Of Operations and Financial Condition,” including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. Attached and incorporated herein by reference as Exhibit 99.1 is a copy of a press release of CME Group Inc. dated July 23, 2025, reporting CME Group Inc.’s financial results for the quarter ended June 30, 2025. To supplement CME Group’s financial statements on a GAAP basis, the attached press release includes financial measures that are not in accordance with GAAP, consisting of non-GAAP net income and earnings per share. Management believes that the presentation of non-GAAP net income and earnings per share provide important supplemental information to management and investors about financial and business trends relating to CME Group Inc.’s financial condition and results of operations. Management believes that the use of these non-GAAP financial measures provide a better measure of comparability with the Company’s prior financial reports. Management acknowledges that non-GAAP adjustments may include recurring items. These non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Pursuant to the requirements of Regulation G, CME Group Inc. has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in the press release.
Item 9.01Financial Statements and Exhibits.
Exhibit Number Description
99.1 Press Release, dated July 23, 2025.
104 The cover page from CME Group Inc.'s Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CME Group Inc. Registrant
Date: July 23, 2025 By: /s/ Lynne Fitzpatrick Name:
Title: Lynne Fitzpatrick
Senior Managing Director, President and Chief Financial Officer
Principal Financial Offer and Duly Authorized Officer
Latest CME Group Inc. News
CME Breaking Stock News: Dive into CME Ticker-Specific Updates for Smart Investing
MT Newswires
CME Group Insider Sold Shares Worth $1,594,440, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Financial Times
US intervention in oil futures would be ‘biblical disaster’, CME warns
📉
AI Sentiment
Negative
3/10
The Wall Street Journal
Investors Are Having Doubts About Interest-Rate Cuts
📉
AI Sentiment
Negative
3/10
Simply Wall St.
How The Investment Story For CME Group (CME) Is Quietly Shifting On Mixed Analyst Signals
📊
AI Sentiment
Positive
7/10
MT Newswires
Rothschild & Co Redburn Adjusts Price Target on CME to $347 From $333, Maintains Neutral Rating
➖
AI Sentiment
Neutral
5/10
PR Newswire
CME Group Inc. Announces First-Quarter 2026 Earnings Release, Conference Call
➖
AI Sentiment
Neutral
5/10
Compare CME vs Leading Stocks
See how CME stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CME CME Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.